BP
RPRX icon

Ballentine Partners’s Royalty Pharma RPRX Stock Holding History

Ballentine Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$506K Sell
9,027
-533
-6% -$27.7K 0.01% 562
2026
Q1 		$459K Sell
9,560
-882
-8% -$38.6K 0.01% 558
2025
Q4 		$403K Buy
10,442
+75
+0.7% +$2.86K 0.01% 587
2025
Q3 		$366K Sell
10,367
-362
-3% -$13.1K 0.01% 623
2025
Q2 		$387K Buy
10,729
+2,955
+38% +$97.9K 0.01% 579
2025
Q1 		$242K Sell
7,774
-72
-0.9% -$2.28K ﹤0.01% 705
2024
Q4 		$200K Buy
+7,846
New +$208K ﹤0.01% 788
2024
Q2 		– Sell
-12,541
Closed -$381K – 793
2024
Q1 		$381K Buy
12,541
+406
+3% +$12K 0.01% 466
2023
Q4 		$341K Buy
+12,135
New +$333K 0.01% 471
2022
Q2 		– Sell
-12,932
Closed -$504K – 475
2022
Q1 		$504K Buy
12,932
+3,819
+42% +$150K 0.02% 255
2021
Q4 		$363K Buy
+9,113
New +$354K 0.01% 334

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
KMC
Kirr Marbach & Co Columbus, Indiana $594M AUM 34% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CI
Cooper Investors Melbourne, Victoria, Australia $218M AUM 0.39% 1-Year Est. Return
KC
Kepler Cheuvreux Nyon $1.75B AUM 37.37% 1-Year Est. Return
BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return

Ballentine Partners's RPRX Position: Q2 2026 in Review

Ballentine Partners reduced its Royalty Pharma (RPRX) stake by 5.6% in Q2 2026, selling an estimated $27.7K and leaving 9,027 shares worth $506K. The position accounts for 0.01% of the portfolio, ranked #562.

Ballentine Partners first reported a position in RPRX in Q4 2021 and has held it in 11 quarters since. 54 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Ballentine Partners held 9,027 shares of Royalty Pharma worth $506K as of Q2 2026.
  • Ballentine Partners sold 533 Royalty Pharma shares in Q2 2026, an estimated $27.7K.
  • Royalty Pharma made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #562 holding.
  • Ballentine Partners first reported a position in Royalty Pharma in Q4 2021 and has held it in 11 quarters since.
  • 54 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.